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See Article, pages 682–689Gold is for the mistress – silver for the maid – copper for the
craftsmen cunning in his trade, ‘‘Good!’’ said the Baron sitting in
his hall, ‘‘But Iron – Cold Iron – is the master of them all!’’
Beyond the metaphorical meaning of iron in Rudyard Kipling’s
famous poem, iron literally is here also described as the most
important transition metal in human biology [1].
Iron’s unique abilities to carry oxygen and to transfer elec-
trons render this element essential for oxidative phosphorylation
and life. Iron therefore is not just an essential nutrient but also a
symbol of power and strength in different cultural contexts.
However, as hepatologists we are all too familiar with the
dark side of iron’s power. In hemochromatosis excess iron is
stored in the liver, heart, endocrine glands and integument,
where it can cause cirrhosis, cardiomyopathy, diabetes and dark-
ening of the skin [2].
Although this clinical description of ‘bronzed diabetes’ is
included in every comprehensive medical textbook, full-blown
hemochromatosis with liver, heart, and endocrine manifestations
is or has become a rare condition [3].
Since phlebotomy, genetic testing and especially insulin have
been introduced, hemochromatosis has turned from a condition
with a dismal prognosis into a curable and even preventable
health problem. Accordingly, several studies have shown that
survival in timely (‘pre-cirrhotic’) and adequately treated hemo-
chromatosis patients does not differ from that expected of a
matched healthy control population [4].
So everything appears to be solved in hemochromatosis,
where the quest for progress may appear just as ridiculous as
one would ask for sustained viral response rates in excess of
100% in the treatment of chronic hepatitis C virus infection.
The ﬁndings reported by Edouard Bardou-Jacquet and
coworkers from Rennes in this issue of the Journal of Hepatology
show that in a subgroup of hemochromatosis patients, survival
is actually better than that of a matched control group [5]. The
ﬁndings raise immediate questions as to why this had not been
observed in previous reports and if this is a result of earlier
diagnosis or phlebotomy? If this was due to the treatment, couldJournal of Hepatology 20
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Open access under CC BY-NC-ND license.phlebotomies have beneﬁcial health effects in other patient
groups as well?
To answer these questions we need to take a closer look at the
data and view the results in the context of previous studies.
The group from Rennes analyzed a large cohort of 1085 con-
secutively diagnosed C282Y homozygous hemochromatosis
patients recruited between 1996 and 2009. Included patients
were treated according to current recommendations and pro-
spectively followed in the LOGIFER cohort. By comparison, one
of the last reports on hemochromatosis outcomes before the
HFE gene had been identiﬁed reported on 251 patients diagnosed
between 1947 and 1991 [4]. Although the prevalence of hemo-
chromatosis certainly differs between Brittany in France and
Nordrhein-Westfahlen in Germany and although both centers
may not necessarily serve an equally sized population, the differ-
ence in calculated annual incidences is remarkable and amounts
to a factor of 14.
The main reason for this difference in our view is the intro-
duction of genetic testing. Since genetic tests have been intro-
duced, hemochromatosis has gradually and subtly changed its
face [6]. This is also reﬂected by the almost equal distribution
between males and females in the LOGIFER cohort, which is in
stark contrast to the previously reported 9:1 distribution
between males and females in the German cohort. Originally,
hemochromatosis was diagnosed as ‘bronzed diabetes’ in
patients with clinical disease manifestations. Liver biopsy, serum
iron parameters, HLA typing and ultimately HFE genotyping have
increased the sensitivity to diagnose hemochromatosis [7].
Accordingly disease severity at presentation has decreased and
the LOGIFER cohort certainly includes individuals, who would
have never developed any clinical manifestation of the disease
even without venesection.
The concept that C282Y homozygosity has a low penetrance
and even untreated C282Y homozygotes have an excellent
prognosis unless ferritin is >1000 lg/L or increases over time,
has emerged from population-based studies [8]. For instance,
when 48 untreated C282Y homozygotes and a large control
population were followed over 15-years, it was found that both
groups had comparable survival rates [9].
In light of the new ﬁndings from the Rennes group, one can no
longer regard equal survival in hemochromatosis and control
population as acceptable. In the LOGIFER cohort, standardized
mortality rates were signiﬁcantly reduced in the subgroups of
patients with hyperferritinemia below 1000 lg/L and in patients15 vol. 62 j 510–511
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with 2 to 10 g iron removed. This reduced mortality was mainly
due to reduced cardiovascular events and reduced extrahepatic
cancer. Furthermore, the data clearly show that phlebotomy does
certainly no harm to this group of patients with mild iron
overload. In accordance with previous reports, the most impor-
tant factors associated with death were alcohol consumption
>30 g/day, presence of liver cirrhosis, and diabetes at the time
of diagnosis. Notably, the standardized mortality rate for liver
cancer associated death in C282Y homozygous hemochromatosis
patients with diabetes was 92, which supports a functional link
between iron, energy metabolism and hepatocellular carcinogen-
esis [10,11].
Finally, can phlebotomy possibly reduce mortality also in
patients with mild to moderate iron overload in the absence of
C282Y homozygozity? Unfortunately, this question cannot be
answered from this study, although some conclusions can be
inferred. First, phlebotomy was also associated with reduced
overall mortality if less than 2 g of iron were removed, although
this observation did no reach statistical signiﬁcance. Furthermore
in patients without ﬁbrosis overall mortality was also reduced,
which was mainly due to lower cardiovascular events and extra-
hepatic cancer. These ﬁndings and encouraging results from
smaller pilot trials in patients with dysmetabolic iron overload
syndrome and metabolic hyperferritinemia provide a strong
rational base for conducting larger controlled multicentric trials
with well-deﬁned endpoints on the effect of phlebotomy in
patients with hyperferritinemia in the context of non-alcoholic
fatty liver disease [12–15].
Until we have the results from such trials, our best advice
‘Hang on! To phlebotomy’ has to be restricted to hemochromato-
sis patients, and the answer to the question raised in the title is
an unambiguous ‘Yes!’.Conﬂict of interest
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